# Reviewer Yns9 — Score: 3 (Weak Accept)
**Confidence: 4 (High)**

## Strengths
- Clinical trial accrual failure is a genuine crisis; RECITE operationalizes expert knowledge
- Clean, scalable benchmark construction pipeline
- 44 concrete matches with peer-reviewed accrual estimates show deployability

## Weaknesses
- **W1: Only oncology** — limits generalizability (acknowledged as good starting point)
- **W2: Accrual gains inherited, not prospectively measured**
- **W3: Evaluation transparency** — LLM-as-judge prompt template not included; no human evaluation protocol for clinicians to replicate
- **W4: No open-weight models >=10B evaluated.** Scaling trends from 2B->9B suggest larger models (Llama-3.1-70B, Qwen3-14B/32B/72B) could differ meaningfully.
- **W5: Binary threshold (>=3 = "largely equivalent") is coarse;** clinically meaningful differences could hide in the 3 vs. 4 bucket.
- **W6: No comparison to human expert judgments** or baseline systems (rule-based extraction, non-agentic LLMs).
- **W7: The repo contains no actual data or instructions to run the code.**
